21:49 , Aug 29, 2018 |  BC Extra  |  Preclinical News

Sequential therapies trigger axon regeneration in spinal cord injury

University of California Los Angeles and Swiss Federal Institute of Technology Lausanne (EPFL) researchers showed delivery of three sequential therapies could trigger axon growth after complete spinal cord injury in rodents, suggesting the combination approach...
23:15 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Neurotech's NT-501 meets in Phase II for macular telangiectasia

Neurotech Pharmaceuticals Inc. (Cumberland, R.I.) reported data from a Phase II trial in 67 patients with macular telangiectasia showing that implanted Renexus (NT-501) met the primary endpoint of reducing progressive loss of photoreceptors from baseline...
07:00 , Jun 13, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Ciliary neurotrophic factor (CNTF) In vitro studies...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Regeneron regulatory update

The University of California (San Francisco) received U.S. Patent No. 5,667,968 covering the use of ciliary neurotrophic factor ( CNTF) to treat retinal diseases such as retinitis pigmentosa and macular degeneration. REGN has an exclusive...
07:00 , Jun 24, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Ciliary neurotrophic factor (CNTF) A study in cell culture and in mice suggests...
07:00 , Apr 8, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology CNS disorders Not applicable In vitro and rodent studies identified triazine-based compounds that could trigger neurite growth...
08:00 , Mar 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Ciliary neurotrophic factor (CNTF) In vitro and rat studies suggest that transplanting oligodendrocyte...
08:00 , Jan 7, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Suppressor of cytokine signaling 3 (SOCS3); ciliary neurotrophic factor (CNTF) Studies in mice suggest that...
07:00 , Sep 24, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Retinitis Rhodopsin (RHO;...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

NT-501: Phase II data

Data from a double-blind Phase II trial in 67 patients with early stage RP showed that the high dose NT-501 implant led to a dose-dependent increase in retinal thickness from baseline to month 12 (p<0.001)....